XT
ENVB icon

XTX Topco’s Enveric Biosciences ENVB Stock Holding History

XTX Topco’s Portfolio ENVB Stock Details ENVB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$26.2K Buy
+18,990
New +$45.6K ﹤0.01% 3856
2025
Q1 		– Sell
-122
Closed -$7.89K – 2582
2024
Q4 		$7.89K Buy
+122
New +$8.85K ﹤0.01% 2174

Other funds holding ENVB

SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
AI
AdvisorShares Investments Bethesda, Maryland $828M AUM 37.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return
SG
StoneX Group New York $2.48B AUM 33.54% 1-Year Est. Return
HF
HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

XTX Topco's ENVB Position: Q2 2026 in Review

XTX Topco opened a new position in Enveric Biosciences (ENVB) in Q2 2026: 18,990 shares worth $26.2K. The stake represents ﹤0.01% of the portfolio and ranks #3856 among its holdings. This is a return to the name: XTX Topco previously reported a position in ENVB as recently as Q4 2024.

XTX Topco first reported a position in ENVB in Q4 2024 and has held it in 2 quarters since. 24 funds tracked by Wall St. Rank hold ENVB as of Q2 2026.

  • XTX Topco held 18,990 shares of Enveric Biosciences worth $26.2K as of Q2 2026.
  • Enveric Biosciences was a new XTX Topco position in Q2 2026.
  • Enveric Biosciences made up ﹤0.01% of XTX Topco's portfolio in Q2 2026, its #3856 holding.
  • XTX Topco first reported a position in Enveric Biosciences in Q4 2024 and has held it in 2 quarters since.
  • 24 funds tracked by Wall St. Rank held Enveric Biosciences as of Q2 2026.

Based on XTX Topco's 13F filing for Q2 2026, filed 14 Aug 2026.